Skip to main content
. Author manuscript; available in PMC: 2020 Feb 12.
Published in final edited form as: Nat Med. 2019 Aug 12;25(9):1422–1427. doi: 10.1038/s41591-019-0542-z

Extended Data Fig. 4: Radiologic response to combined TRK/MET inhibition in Patient 3 correlates with decreased allele frequency of the targeted alterations in cfDNA.

Extended Data Fig. 4:

a, Graph depicting the allele frequencies of the truncal NTRK fusion in the cfDNA of the PLEKHA6-NTRK1 positive cholangiocarcinoma patient (Patient 3) while treated with LOXO-195 and the combination of LOXO-195 and crizotinib. The time on treatment, best clinical response (SD: stable disease based on RECIST v1.1 criteria) and the time of progression (POD) for each of the indicated therapeutic regimens are displayed. b, Copy number plots from this patient demonstrating disappearance of the MET amplification on treatment and reemergence at the time of disease progression.